Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  D'Addario, G ^a   Fruh M ^b   Reck, M ^c   Baumann, P ^d   Klepetko, W ^e   Felip, E ^f  

^a Onkologie Schaffhausen   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c KRANKENHAUS GROSSHANSDORF   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; TAXANE DERIVATIVE; TETRACYCLINE;

ADRENAL METASTASIS; ADRENALECTOMY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; DISEASE MARKER; DRUG RESPONSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURODESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; STEREOTACTIC RADIOSURGERY;

EID: 77954321859     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq189     Document Type: Article

References (34)

1. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008; 44: 1345-1389.
2. Borràs JM, Fernandez E, Gonzalez JR et al. Lung cancer mortality in European regions. Ann Oncol 1955-1997; 2003(14): 159-161.
3. Verdecchia A, Francisci S, Brenner H et al. the EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
4. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer 2009; 126: 1454-1466.
5. Travis WD, Brambilla E, Müller-Hermelink HK et al. WHO Classification: Pathology and Genetics of Tumours of the Lung, Pleura. Thymus and Heart. Lyon: IARC Press 2004.
6. Sequist LV, Martins RG, Spigel D et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-2449.
7. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-3346.
8. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
9. Kobayashi K, Inoue A, Maemondo M et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009; 27 (15 Suppl): Abstr 8016.
10. Tsurutani J, Mitsudomi T, Mori S et al. A phase III, first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene. ESMO/ECCO 2009 Abstr O-9002.
11. Mok TS, Wu Y, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
12. IASLC Staging Manual in Thoracic Oncology Staging 2009.
13. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
14. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
15. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
16. Rajeswaran A, Trojan A, Burnand B et al. Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first-line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59: 1-11.
17. Hotta K, Fujiwara Y, Matsuo K et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007; 109: 939-948.
18. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007; 57: 348-358.
19. Ardizzoni A, Boni L, Tiseo M et al. For the CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007; 99: 847-857.
20. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
21. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
22. Pirker R, Pereira JR, Szczesna A et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009; 373: 1525-1531.
23. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
24. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
25. Langer CJ, Manola J, Bernado P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.
26. Fidias PM, Dakhir SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 591-598.
27. Cappuzzo F, Coudert BP, Wierzbicki et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study; World Conference on Lung Cancer 2009 Abstr A2.1.
28. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
29. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
30. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 22(372): 1809-1818.
31. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
32. Di Maio M, Chiodini P, Georgoulias V et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 1836-1843.
33. Tan C, Serdakyan A, Browne J et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29: 829-838.
34. Burt M, Wronski M, Arbit E et al. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. J Thorac Cardiovasc Surg 1992; 103: 399-410.